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Summary
Overexpression of Bcl-xL, loss of p19
ARF, and loss of p53 all accelerate Myc oncogenesis. All three lesions are implicated in
suppressing Myc-induced apoptosis, suggesting that this is a common mechanism by which they synergize with Myc.
However, using an acutely switchable model of Myc-induced tumorigenesis, we demonstrate that each lesion cooperates
with Myc in vivo by a distinct mechanism. While Bcl-xL blocks Myc-induced apoptosis, inactivation of p19
ARF enhances it.
However, this increase in apoptosis is matched by increased Myc-induced proliferation. p53 inactivation shares features
of both lesions, partially suppressing apoptosis while augmenting proliferation. Bcl-xL and p19
ARF loss together synergize
to further accelerate Myc oncogenesis. Thus, differing lesions cooperate oncogenically with Myc by discrete mechanisms
that can themselves synergize with each other.Introduction
The tumorigenic consequences of oncogene activation are re-
strained by intrinsic tumor suppression pathways, of which the
best characterized are induction of apoptosis and proliferative
arrest (Evan and Vousden, 2001; Lowe et al., 2004). As a conse-
quence, tumorigenesis can arise only as a result of multiple,
complementary oncogenic lesions that cooperate to defuse the
intrinsic tumor suppressor pathways triggered by each other.
For this reason, individual oncogenic mutations are, typically,
highly inefficient at driving tumorigenesis in individual somatic
cells. The oncogene c-myc is a well-characterized example
of this phenomenon. c-myc encodes a member of the basic-
helix-loop-helix-leucine zipper transcription factor family, Myc,
that coordinates expression of many diverse genes involved in
processes necessary for cell expansion, including cell growth,
metabolism, ribosome biogenesis, proliferation, and differentia-
tion (Adhikary and Eilers, 2005; Hurlin and Dezfouli, 2004). This
central role in cell expansion underlies the frequent selection
for deregulation and/or overexpression of Myc in many human
tumors. At the same time, aberrant Myc expression is also
a powerful promoter of apoptosis, an intrinsic tumor suppressorCANCER CELL 10, 113–120, AUGUST 2006 ª2006 ELSEVIER INC. DOImechanism that serves as a powerful inbuilt restraint to Myc’s
oncogenic action. By specifically gating the intrinsic apoptotic
Myc tumor suppressor pathway, mutations that suppress apo-
ptosis, such as overexpression of members of the antiapoptotic
Bcl-2/Bcl-xL family (Bissonnette et al., 1992; Fanidi et al., 1992;
Pelengaris et al., 2002; Wagner et al., 1993), potently cooperate
with Myc to drive tumorigenesis (Strasser et al., 1990).
As with many other dominant oncoproteins, activated Myc
triggers p53 via the induction of the tumor suppressor p19ARF.
Loss of either p19ARF (Eischen et al., 1999; Schmitt et al.,
1999) or p53 (Elson et al., 1995; Hsu et al., 1995), like overex-
pression of Bcl-2, greatly accelerates Myc oncogenesis in
a wide variety of transgenic mouse tumor models. Several stud-
ies suggest that loss of either p19ARF (Zindy et al., 1998) or p53
(Hermeking and Eick, 1994; Wagner et al., 1994) suppresses
Myc-induced apoptosis in fibroblasts in vitro, although such
studies are complicated by the need for serum deprivation to
trigger such Myc-dependent apoptosis because withdrawal of
serum, a potent cocktail of inflammatory mitogens and survival
factors, is a powerful promoter of both proliferative arrest and
cell death in its own right. More recently, studies using trans-
genic and transplanted Myc-induced lymphoma models haveS I G N I F I C A N C E
Apoptosis is a crucial intrinsic tumor suppressor mechanism that limits Myc’s oncogenic potential. Here, we ask whether all oncogenic
lesions that cooperate with Myc in vivo do so by suppressing apoptosis. We show that Bcl-xL overexpression, loss of p19
ARF, and loss of
p53 each cooperate with Myc by a distinct mechanism. Bcl-xL blocks apoptosis, whereas inactivation of p19
ARF enhances both Myc-
induced apoptosis and Myc-induced proliferation, generating a tissue with roughly normal cell numbers but greatly increased cell
turnover. p53 augmentsMyc-induced proliferation but also affords partial protection from apoptosis, thus establishing a highly aggres-
sive tumor phenotype. Thus, oncogenes cooperate by discrete mechanisms, suggesting that there are multiple ways by which the
balance between cell gain and cell loss might be reestablished therapeutically in tumors.10.1016/j.ccr.2006.06.017 113
are not merely a trivial consequence of suppression of insulin
A R T I C L Eindicated that inactivation of apoptosis through overexpression
of Bcl-2 or loss of Bax relieves selective pressures to lose p53
function during lymphomagenesis (Eischen et al., 2001; Schmitt
et al., 2002), again hinting that p53 functions to mediate Myc-
induced apoptosis in such models. On the other hand, there
are many known instances where a functional p19ARF/p53 path-
way is not required for Myc-induced apoptosis. For example,
Myc-induced apoptosis is independent of p53 in Myc-induced
lymphoma (Hsu et al., 1995), as is Myc-dependent apoptosis
(Lenahan and Ozer, 1996) and release of mitochondrial holocy-
tochrome c (Juin et al., 1999) in fibroblasts in vitro, intimating
that loss of p53 would offer no protection from apoptosis in
such instances. The role of p19ARF in Myc-induced apoptosis
is even less clear, given that inactivation of apoptosis through
Bax loss fails to relieve any pressure on loss of p19ARF function
during lymphomagenesis (Eischen et al., 2001). Together, such
observations suggest that loss of p19ARF and/or p53 may pro-
mote Myc-induced tumorigenesis by mechanisms other than
apoptosis suppression. Since both p19ARF (Kamijo et al.,
1998; Kuo et al., 2003) and p53 (Lowe et al., 2004) exert pro-
found antiproliferative influences, one plausible possibility is
that loss of p19ARF and/or p53 serves to abrogate an intrinsic
antiproliferative pathway triggered by Myc activation.
Classical transgenic and knockout mouse tumor models pos-
sess constitutively preconfigured genetic backgrounds that pre-
dispose them to neoplasia, but they rely on sporadic, uncon-
trolled, and largely unknown secondary lesions to precipitate
the actual onset and progression of tumors. Many studies indi-
cate that combining different, hardwired transgenic or knockout
lesions can accelerate or retard tumorigenesis. However, the
rarity of the eventual clonal tumors that emerge among all the
target somatic cells, the extended time over which they do so,
and the arcane nature of the additional sporadic lesions that
are required all mean that it is not possible to infer back from tu-
mor incidence studies how such hardwired lesions interacted in
the normal cells from which the tumor evolved. To circumvent
this problem, we have employed a reversibly switchable model
of Myc oncogenesis in which the timing of the initial Myc activa-
tion event is precisely known and controlled within the target tis-
sue. This allows real-time monitoring of the interaction between
Myc and any other oncogenic lesions during the earliest stages
of tumor initiation through progression and into tumor mainte-
nance. Here, we use a version of this switchable model of Myc-
induced oncogenesis in b cells (Pelengaris et al., 2002) to com-
pare directly the impact of an antiapoptotic lesion, Bcl-xL, and
inactivation of either p19ARF or p53 in modulating the capacity
of Myc to initiate and drive tumorigenesis in vivo.
Results
Bcl-xL expression, ARF loss, and p53 loss each elicit
a distinct outcome following Myc activation
in pancreatic b cells
In pIns-MycERTAM mice, expression of the acutely and revers-
ibly switchable MycERTAM protein is driven specifically in pan-
creatic b cells from the mouse insulin promoter. As previously
described (Pelengaris et al., 2002), acute activation of Myc in
pIns-MycERTAM mice induces rapid onset of both proliferation
and apoptosis, the latter overwhelming the former and leading
to rapid b cell depletion (Pelengaris et al., 2002). Coexpression
of the apoptosis suppressor Bcl-xL in b cells efficiently blocks114Myc-induced b cell apoptosis, and as a consequence, sustained
Myc activation in such pIns-MycERTAM;RIP7-Bcl-xL mice drives
progressive b cell expansion synchronously in all pancreatic is-
lets. Such expansion is concomitant with progressive acquisi-
tion of classical attributes of tumorigenesis, including dediffer-
entiation, tissue dysplasia and remodeling, angiogenesis, local
invasion, and metastasis (Pelengaris et al., 2002). Hence, sup-
pression of the intrinsic Myc-driven apoptotic program is suffi-
cient to expose the oncoprotein’s multifarious tumorigenic
potential.
Many studies have implicated the p53 pathway in mediation
of Myc-induced apoptosis. The critical conduit by which onco-
genic Myc activates p53 is the tumor suppressor p19ARF (Zindy
et al., 1998) and, consistent with this, inactivation or loss of
p19ARF or p53 exhibits dramatic oncogenic synergy with Myc
(Eischen et al., 1999; Schmitt et al., 1999). To assess whether,
and how, loss of either ARF or p53 synergizes oncogenically
withMyc in our switchable b cell model, we activatedMycERTAM
in b cells of ARF2/2 or p532/2mice and examined b cell dynam-
ics in each case, using BrdU incorporation to assess b cell pro-
liferation and TUNEL staining to monitor apoptosis. As de-
scribed, activation of Myc for 3 days in pIns-MycERTAM b cells
induces both apoptosis and proliferation (Figures 1A and 1E),
while Bcl-xL overexpression in the pIns-MycER
TAM;RIP7-Bcl-
xL bitransgenic mice blocks Myc-induced apoptosis (Figure 1B)
but allows proliferation to drive net b cell expansion (Figure 1F).
Thus, Bcl-xL cooperates with Myc by selectively blocking the in-
trinsic apoptotic tumor suppressor function of Myc. By contrast,
analogous analysis of proliferation and apoptosis in ARF2/2
b cells following Myc activation revealed no measurable sup-
pression of apoptosis compared with that in ARFwt controls
(Figure 1C). Indeed, TUNEL staining indicated a 2.5-fold in-
crease in apoptosis at 72 hr post-Myc activation in ARF2/2
b cells (9.9% apoptosis in pIns-MycERTAM mice versus 25.2%
in pIns-MycERTAM;ARF2/2mice). However, this increased apo-
ptosis was accompanied by a marked increase in b cell prolifer-
ation over that in ARFwt or Bcl-xL-overexpressing b cells (Fig-
ure 1G): at 72 hr after Myc activation BrdU incorporation
was w3-fold higher in the absence of ARF (3.3% 6 0.06% in
pIns-MycERTAM mice, 4.9% 6 1.85% in pIns-MycERTAM;RIP7-
Bcl-xL mice, and 10.2% 6 1.08% in pIns-MycER
TAM;ARF2/2
mice). Activation of Myc in p532/2 b cells also induced apopto-
sis, although thiswas partially suppressed comparedwith b cells
from pIns-MycERTAM mice (from 9.9% down to 5.6%; Fig-
ure 1D). Analysis of BrdU incorporation revealed that p53 loss
augmented Myc-induced b cell proliferation relative to that in
pIns-MycERTAM;RIP7-Bcl-xL b cells, to a degree similar to that
seen in the absence of p19ARF (Figure 1H; BrdU incorporation
of 13.6% 6 4.1%), consistent with the antiproliferative effects
of p19ARF being, in great part, p53 dependent.
The enhancement of Myc-induced b cell proliferation
conferred by ARF loss is not due to increased expression
of the MycERTAM transgene
Activity of the insulin promoter element used to drive expression
of MycERTAM in the pIns-MycERTAM model is potentially sensi-
tive to the differentiation status of b cells (Pelengaris et al.,
2002). Since Myc is known to suppress differentiation in many
cell lineages, we needed to confirm that the changes we ob-
serve inMyc-driven proliferation in various genetic backgroundsCANCER CELL AUGUST 2006
A R T I C L EFigure 1. Bcl-xL overexpression, p19
ARF loss, and
p53 loss each modulate Myc’s oncogenic po-
tential by distinct mechanisms
Myc was activated in b cells of pancreatic
islets of pIns-MycERTAM (A, E, I, and M),
pIns-MycERTAM;RIP7-Bcl-xL (B, F, J, and N), pIns-
MycERTAM;ARF2/2 (C, G, K, and O), or pIns-
MycERTAM;p532/2 (D, H, and L) mice for 3 days.
3.5 hr prior to sacrifice, BrdU was administered
systemically. Pancreas sections were stained for
apoptosis by TUNEL (gray with eosin counter-
stain) (A–D), with anti-BrdU (green) plus anti-insu-
lin (red) and Hoechst (blue) counterstain (E–H) to
identify S phase b cells, or with anti-insulin (I–L) or
anti-ERa (M–O) followed by excess fluorescent
secondary antibody to allow quantitative imag-
ing. A quantitative color scale is shown below O.
‘‘b’’ denotes islets. Scale bars are 100 mm (A–D)
and 20 mm (E–O). The occasional bright punc-
tate fluorescent staining seen in the anti-insulin-
stained sections correlates with apoptotic cells
and is evident in islets from all but the pIns-
MycERTAM;RIP7-Bcl-xL mice.promoter-driven MycERTAM expression. To address this, tissue
sections were stained with anti-insulin antibody and insulin ex-
pression levels assayed by quantitative immunofluorescence.
After 3 days Myc activation, insulin expression was comparable
in pIns-MycERTAM mice and in pIns-MycERTAM;RIP7-Bcl-xL
bitransgenic mice (Figures 1I and 1J) and somewhat
decreased in b cells of pIns-MycERTAM;ARF2/2 and pIns-
MycERTAM;p532/2 mice (Figures 1K and 1L). Given the inverse
relationship between Myc-induced proliferation and terminal
differentiation in b cells (Laybutt et al., 2002), as in many other
cell lineages, this decrease in insulin staining is consistent with
the increased proliferation that we observe in ARF2/2 and
p532/2 b cells. Since the insulin promoter drives expression of
the MycERTAM transgene, these data suggest that expression
of MycERTAM is, if anything, lower in ARF2/2 and p532/2 mice
than in pIns-MycERTAM;RIP7-Bcl-xL animals.
We used quantitative immunofluorescence analysis of ERa
immunoreactivity to ascertain directly levels of MycERTAM in
b cells. This showed that expression of MycERTAM was roughly
equivalent in the ARFwt and ARF2/2 backgrounds (Figures 1M
and 1O), both of which were significantly less than in pIns-
MycERTAM;RIP7-Bcl-xL b cells (Figure 1N). This is despite the
fact that Myc-induced b cell proliferation is markedly lower in
pIns-MycERTAM;RIP7-Bcl-xL b cells than in b cells of ARF
2/2
mice. No ERa immunoreactivity was observed in nontransgenic
islets (data not shown). While decreased expression of the insu-
lin promoter-drivenMycERTAM transgene in ARF2/2 b cells rela-
tive to their pIns-MycERTAM;RIP7-Bcl-xL counterparts may be
a consequence of their increased proliferation and concomi-
tantly depressed terminal differentiation, it is also possible that
b cells expressing high levels of MycERTAM are preferentially
eradicated by apoptosis in ARF2/2 animals, whereas such se-
lective culling is blocked in pIns-MycERTAM;RIP7-Bcl-xL b cells.
Whatever the explanation, however, it is clear that the enhanced
Myc-induced proliferation observed in ARF2/2 b cells is not dueCANCER CELL AUGUST 2006to elevatedMycERTAM expression: indeed, it occurs despite sig-
nificant MycERTAM downregulation in p19ARF-deficient b cells.
Enhanced Myc-induced proliferation in b cells lacking
p19ARF or p53 correlates with a failure of Myc
to induce p21cip1
Myc is a potent inducer of the cell cycle inhibitor p21cip1. This in-
duction requires both ARF and p53 (Zindy et al., 1998), providing
a potential mechanism for the enhanced proliferation afforded
by Myc in ARF- and p53-deficient b cells. We therefore assayed
the expression of p19ARF, p53, and p21cip1 followingMyc activa-
tion in b cells in vivo by immunofluorescence. Activation of
Myc strongly induced p19ARF in both pIns-MycERTAMmice (Fig-
ures 2A and 2B) and pIns-MycERTAM;RIP7-Bcl-xL mice (data
not shown). Myc also induced accumulation of p53 (Figures 2C
and 2D), although much of this appeared to be p19ARF indepen-
dent (Figures 2E and 2F). Both p19ARF upregulation and p53
stabilization were accompanied by strong induction of nuclear
p21cip1 (Figures 2G and 2H). By contrast, in both pIns-
MycERTAM;ARF2/2 and pIns-MycERTAM;p532/2mice, induction
of p21cip1 by Myc was strongly suppressed (Figures 2I and 2J).
Thus, the enhanced pro-proliferative activity of Myc in p19ARF-
and p53-deficient b cells correlates with a failure of Myc to
induce p21cip1 in these genetic backgrounds.
Bcl-xL overexpression and p19
ARF loss synergize
with each other to augment Myc’s oncogenic activity
Our data demonstrate that gain of function in Bcl-xL and loss
of p19ARF function cooperate oncogenically with Myc in b cells
in vivo by fundamentally distinct mechanisms: Bcl-xL specifi-
cally blocks Myc-induced apoptosis while permitting Myc-
induced proliferation, whereas loss of p19ARF augments Myc-
induced proliferation, possibly through disruption of the p53/
p21cip1 axis, to the extent that it balances or exceeds cell loss
through apoptosis. One prediction from these observations is115
A R T I C L Ethat the combination of both Bcl-xL overexpression and p19
ARF
loss together should greatly accelerate Myc-induced tumori-
genesis over either one alone. To test this directly, we crossed
the pIns-MycERTAM;RIP7-Bcl-xL mice onto our ARF-deficient
background and activated MycERTAM in b cells for 12 days to
induce tumor formation. First, we assessed whether the two
lesions could indeed synergistically cooperate with Myc activa-
tion. Ki67 staining and TUNEL analysis revealed that the mech-
anistic differences between Bcl-xL overexpression and p19
ARF
loss that we observed after 3 days of sustained Myc activation
(Figure 1) aremaintained at the later times (12 days). Thus, b cells
from the pIns-MycERTAM;RIP7-Bcl-xL mice exhibit relatively
modestMyc-dependent proliferation combined with a complete
absence of apoptosis (Figures 3A and 3E), while b cells from
pIns-MycERTAM/ARF2/2 mice exhibit a high proliferative rate
together with high apoptosis (Figures 3B and 3F). b cells from
pIns-MycERTAM/p532/2mice also behaved as expected, exhib-
iting a high proliferative rate with partial incomplete suppression
of apoptosis (Figures 3C and 3G). As predicted, b cells from
the pIns-MycERTAM;RIP7-Bcl-xL;ARF
2/2 mice combined the
features of each separate cooperatingmutation, exhibiting com-
plete absence of apoptosis together with a high rate of prolifer-
ation (Figures 3D and 3H).
To assess the influence of the differing cooperating lesions on
overt Myc-induced b cell tumorigenesis, we examined the histo-
logical characteristics of the 12 day b cell tumors in each case.
As described previously (Pelengaris et al., 2002), 12 days of sus-
tained Myc activation alone in pIns-MycERTAM mice triggers
involution of all islets due to overwhelming apoptosis of virtually
Figure 2. Myc-dependent induction of p21cip1 requires functional p19ARF
and p53
Sections from 1 day (A and B) or 3 day (C–J) islets from control oil (Myc
OFF)- or tamoxifen (Myc ON)-treated pIns-MycERTAM (A–D, G, and H), pIns-
MycERTAM;ARF2/2 (E, F, and I), or pIns-MycERTAM;p532/2 mice (J) were
stained with anti-p19ARF antibody (green) plus anti-ER counterstain (red)
(A and B), anti-p53 antibody (green) (C–F), or anti-p21 antibody (green)
with insulin counterstain (red) (G–J). Myc activation induces upregulation
of p19ARF and p21. The upregulation of p21cip1 is dependent upon the pres-
ence of p19ARF and p53. Occasional nonnuclear green staining (H–J) is due
to tissue autofluorescence. Scale bars are 20 mm (A–F) and 10 mm (G–J).116all pancreatic b cell populations, resulting in diabetes. Suppres-
sion of Myc-induced apoptosis by coexpression of Bcl-xL ex-
poses Myc’s diverse oncogenic potential, driving expansion
and tumorigenesis of each b cell population in each islet (Fig-
ure 3I). These mice develop transient diabetes (due to Myc-
induced partial dedifferentiation and consequent reduction in
insulin secretion), but their blood glucose subsequently returns
to normal due to steady expansion of the b cell compartment
(Pelengaris et al., 2002). In ARF2/2 mice, Myc-induced b cell
apoptosis is more or less offset by the enhanced rate of Myc-
induced proliferation, resulting in dramatically increased b cell
turnover but little overall change in b cell mass over time (Fig-
ure 3J). This amalgam of Myc-induced dedifferentiation and
lack of overall b cell expansion eventually leads to diabetes
(a rise in blood glucose from 69 mg/dl 6 23 mg/dl prior to treat-
ment to 324 mg/dl 6 158 mg/dl at day 12 after treatment). In
p532/2 animals, enhanced Myc-induced proliferation plus par-
tial suppression of apoptosis drives a more rapid overall b cell
expansion than that observed in Bcl-xL-expressing mice (Fig-
ure 3K). In pIns-MycERTAM;RIP7-Bcl-xL;ARF
2/2mice, the com-
bination of enhanced proliferation together with abrogation of
apoptosis promotes extremely rapid and progressive b cell
tumorigenesis that is so extensive as to occupy the majority
of the central portion of the pancreas after only 12 days (Fig-
ure 3L). Such mice remained free from diabetes throughout
(blood glucose of 151 mg/dl 6 31 mg/dl, within the normal
range for C57Bl6 mice), presumably because massive ex-
pansion of the b cell compartment compensates for their partial
dedifferentiation.
Figure 3. Bcl-xL overexpression, loss of p19
ARF, and loss of p53 each synergize
with Myc by discrete mechanisms to promote tumorigenesis
Myc wasactivatedfor12days inpancreaticbcells ofpIns-MycERTAM;RIP7-Bcl-
xL (A, E, and I), pIns-MycER
TAM;ARF2/2 (B, F, and J), pIns-MycERTAM;p532/2
(C, G, and K), or pIns-MycERTAM;RIP7-Bcl-xL;ARF
2/2 (D, H, and L) mice.
Pancreas sections were stained with anti-Ki67 (A–D, dark brown with eosin
counterstain), by TUNEL (E–H, brown with hematoxylin counterstain) or anti-in-
sulin (gray/blue with eosin counterstain [I–L]). Examples of islets are indicated
by ‘‘b.’’ Scale bars are 20 mm (A–H) and 500 mm (I–L). ex, exocrine tissue.CANCER CELL AUGUST 2006
A R T I C L EBy several criteria, Myc-induced tumorigenesis in the pIns-
MycERTAM;RIP7-Bcl-xL;ARF
2/2 mice is far more severe than
that in either pIns-MycERTAM;RIP7-Bcl-xL or pIns-MycER
TAM;
ARF2/2 animals. Twelve day tumors induced by Myc in pIns-
MycERTAM;RIP7-Bcl-xLmice appear relatively benign, with clear
boundaries between tumor and exocrine tissue (Figure 4A). Islets
in comparably treated pIns-MycERTAM;ARF2/2 mice appear
loculated with irregular boundaries with adjacent exocrine tis-
sue, consistent with the extensive turnover and remodeling of
the b cell compartment in such animals (Figure 4B). In contrast,
12 day b cell tumors in pIns-MycERTAM;RIP7-Bcl-xL;ARF
2/2
mice are massive, typically merging into large clusters with
highly irregular boundaries fromwhich invasive strands of b cells
protrude far into the exocrine tissue (Figure 4C). b cell tumors in
p532/2mice in which Myc had been activated for 12 days were
similarly large, irregular, and invasive (Figure 4F). The large Myc-
induced b cell tumors in both pIns-MycERTAM;RIP7-Bcl-xL;
ARF2/2 and p532/2micewere extensively infiltrated by tortuous
and highly hemorrhagic vasculature (Figures 4D, 4G, 4J, and
4K). Still longer (21 day) sustained activation of Myc in pIns-
MycERTAM;RIP7-Bcl-xL;ARF
2/2mice drove progressive expan-
sion and elaboration of the b cell tumors, leading to a dramatic
hemorrhagic tumor phenotype (Figure 4E). Despite the overt
similarities in overall rapid growth rate and general severity of
b cell tumors in pIns-MycERTAM;RIP7-Bcl-xL;ARF
2/2 mice and
p53-deficient animals, however, the two phenotypes remain
distinct. Apoptosis is virtually absent from all Myc-induced
tumors in pIns-MycERTAM;RIP7-Bcl-xL;ARF
2/2 mice but per-
sists at appreciable levels in p53-deficient animals.
Discussion
Myc, like other dominant oncoproteins, triggers potent intrinsic
tumor suppression pathways that curtail its otherwise powerful
and pleiotropic oncogenic potential. Such tumor suppressor
pathways in effect mask any immediate selective advantage
that Myc activation would otherwise confer upon a somatic cell
target (Lowe et al., 2004). As a consequence, Myc can drive
oncogenesis only when such antagonistic pathways are either
inactivated or sufficiently overwhelmed to allow net cell gain
to prevail over cell loss. Apoptosis is the best-characterized
intrinsic tumor suppressor pathway triggered by Myc, and sev-
eral acute Myc activation models have demonstrated how sup-
pression of apoptosis, either by antiapoptotic mutations such
as overexpression of Bcl-2/Bcl-xL (Bissonnette et al., 1992;
Fanidi et al., 1992; Pelengaris et al., 2002; Wagner et al., 1993)
or through the action of survival signals (Harrington et al., 1994;
Pelengaris et al., 1999), directly potentiates Myc’s oncogenic
function. The p19ARF/p53 pathway is strongly implicated in the
mediation ofMyc-induced intrinsic tumor suppression pathways
(reviewed in Evan and Vousden, 2001): loss of either p19ARF or
p53 greatly accelerates Myc oncogenesis in a wide variety of
cell and tissue types, and selective loss of either p19ARF or p53
is a common feature of Myc-induced tumors in several trans-
genic Myc mouse tumor models. However, since the p19ARF/
p53 pathway is capable of triggering either apoptosis or replica-
tive arrest, depending upon cell type and circumstance, it has
remained unclear which of these two discrete programs is the
principal conduit of tumor suppression in any instance.
We compared the direct mechanisms by which Bcl-xL over-
expression, ARF inactivation, and p53 loss each promote Myc’sCANCER CELL AUGUST 2006oncogenic function in vivo using an acutely switchable model
of Myc oncogenesis targeted to pancreatic b cells. One of
the major shortcomings of classical transgenic and knockout
cancer models is that tumors arise sporadically and only after
significant lag periods, implying that tumorigenesis requires
additional, sporadic, and undefined oncogenic lesions. This is
the case even when multiple cooperating mutations are com-
bined and makes it impossible to assess whether the original
lesions interact directly or indirectly, or by what mechanisms
the cooperation arises. As is clear from evolutionary biology,
acquisition of disadvantageous traits can, by constraining sub-
sequent evolutionary trajectories, be every bit as influential in
fostering success of eventual winners as acquisition of advanta-
geous ones (Lenski et al., 2003). There is therefore no reason to
assume that two mutations that together accelerate tumor for-
mation necessarily confer any immediate selective advantage
on the progenitor tumor cell in which they arise. In contrast to
classical Myc transgenics, acutely switchableMycmodels allow
direct inspection, in real time, of the influence of ancillary
Figure 4. Myc-induced b cell tumors in pIns-MycERTAM;RIP7-Bcl-xL;ARF
2/2
and pIns-MycERTAM;p532/2 are rapidly growing, aggressive, invasive, and
angiogenic
Sections from 12 day (A–D and F–K) or 21 day (E) tumors of the indicated
genotypes were stained with H&E (A–G) or anti-CD31 (H–K, in brown with
eosin counterstain). Note the ragged edges of the islets from pIns-
MycERTAM;ARF2/2 mice (B), indicating an invasive phenotype, despite
lack of overall islet expansion. Myc-induced b cell tumors in pIns-
MycERTAM;RIP7-Bcl-xL;ARF
2/2 mice have invasive and ragged margins (C)
with extensive, tortuous, and hemorrhagic vasculature (D and J). After 21
days of sustained Myc activity in pIns-MycERTAM;RIP7-Bcl-xL;ARF
2/2 mice,
b cell tumor mass occupies the majority of the pancreas (Figure 3L). Tumors
in pIns-MycERTAM;p532/2mice are also highly invasive (F) with extensive and
hemorrhagic angiogenesis (G and K). Examples of islets are indicated by
‘‘b’’ and exocrine pancreas by ‘‘ex.’’ Scale bars are 20 mm (A–D and F)
and 100 mm (E and G–K).117
A R T I C L Eoncogenic lesions on both acute and sustained Myc action in
target tissues residing in their orthotopic environments in vivo.
Furthermore, because the pancreatic b cells harboring switch-
able Myc are distributed among hundreds of independent
islet populations throughout the mouse pancreas, each pIns-
MycERTAM mouse is effectively several hundred independent,
simultaneous tumorigenesis experiments. In the case of each
of the cooperating lesions that we have investigated, Myc acti-
vation is sufficient to induce synchronous and rapid b cell tumor-
igenesis in essentially every one of the several hundred islets in
the pancreas, indicating that no additional sporadic lesions are
required. Such models therefore permit direct inspection, in real
time, of the mechanism by which cooperating lesions modulate
Myc’s oncogenic potential at different stages of tumor growth
in vivo.
Using our acutely switchable pIns-MycERTAM b cell model, we
demonstrate that, although Bcl-xL overexpression, p19
ARF loss,
and p53 inactivation all cooperate oncogenically with Myc, each
lesion appears to cooperate by a distinct mechanism. In partic-
ular, whereas Bcl-xL overexpression cooperates oncogenically
with Myc by specifically blocking Myc-induced apoptosis,
ARF loss cooperates by facilitating Myc-induced proliferation.
The most dramatic consequence of this is that overexpression
of Bcl-xL and loss of p19
ARF themselves synergize with each
other to dramatically potentiate the oncogenic potential of
Myc relative to each alone. Interestingly, mere absence of
p19ARF is insufficient to allowMyc to drive widespread b cell ex-
pansion because the augmented proliferative capacity it affords
is accompanied by a compensatory increase in apoptosis. Con-
sequently, the only net consequence of Myc activation is that
b cells inARF2/2 islets turn over at a greatly enhanced rate com-
pared with thew60 day half-life of normal b cells (Bonner-Weir,
2000). Nonetheless, the balance between increased cell prolifer-
ation and cell death in pIns-MycERTAM/ARF2/2 islets appears to
be very finely poised since, on occasions, we have observed the
occasional individual pancreatic islet to undergo significant
Myc-induced expansion. We note with interest that the apopto-
tic response to Myc is actually increased in the absence of
p19ARF. Possibly this indicates that stresses associated with ab-
errant proliferation are the direct cause of apoptosis and that
p19ARF, by acting as a brake to such aberrant proliferation,
serves to limit the apoptotic impact of Myc. That the same in-
crease in apoptosis does not accompany p53 loss is presum-
ably because p53, unlike p19ARF, partakes directly in the cellular
apoptotic response to aberrant proliferation through its direct
links with the Puma/Noxa/Bax apoptotic machinery.
Overexpression of members of the antiapoptotic Bcl-2/Bcl-xL
protein family has been shown to suppress cell cycle entry in
several cell types (Brady et al., 1996; Huang et al., 1997; O’Reilly
et al., 1996) by a mechanism involving suppression of mitogenic
E2Fs (Vairo et al., 2000). Since mitogenic E2Fs can be potent in-
ducers of p19ARF, we therefore considered the possibility that
p19ARF loss contributes to increased proliferation of Bcl-xL-
expressing b cells by abrogating Bcl-xL-dependent suppression
of b cell proliferation rather than by enhancingMyc-induced pro-
liferation per se. While we cannot exclude the possibility that
such additional interactions further enhance the synergy be-
tween Bcl-xL overexpression and p19
ARF loss, the similarity in
b cell proliferative indices in the pIns-MycERTAM single versus
the pIns-MycERTAM;RIP7-Bcl-xL double transgenic islets fol-
lowing Myc activation suggests otherwise. Another conceivable118mechanism by which p19ARF loss could accentuate Myc-
induced proliferation is suggested by recent observations that
p19ARF can directly interact with, and potentially inhibit, Myc’s
protein function (Datta et al., 2004; Qi et al., 2004). However,
this would not explain why a similar enhancement of Myc’s pro-
liferative capacity is also observed in p532/2 b cells that retain
wild-type p19ARF (Figure 1) or why it is that Myc-induced prolif-
eration is inhibited by p19ARFwhileMyc-dependent suppression
of terminal differentiation is not (Figure 1).
Our previous studies using switchable Myc mouse tumor
models demonstrated that, once apoptosis is abrogated, Myc
instructs multiple aspects of the malignant phenotype, including
cell growth, proliferation, dedifferentiation, tumor angiogenesis,
and invasion (Pelengaris et al., 1999, 2002). It is therefore note-
worthy that the extents of both angiogenesis and invasion, es-
tablished hallmarks of more advanced tumorigenesis, correlate
closely with the degree of Myc-induced proliferation we see in
incipient Myc-induced tumors. Thus, the rapidly expanding
Myc-induced tumors arising in the pIns-MycERTAM;p532/2
and pIns-MycERTAM;RIP7-Bcl-xL;ARF
2/2 mice exhibit a far
more severe invasive and angiogenic phenotype than those
arising in pIns-MycERTAM;RIP7-Bcl-xL animals.
Our data indicating that p19ARF is irrelevant for mediating
Myc-induced apoptosis would seem to be at odds with several
elegant studies using Myc-driven lymphomagenesis models in
the mouse. These have shown that suppression of apoptosis
by Bcl-2 overexpression or Bax loss relieves pressure to inacti-
vate the p53 pathway during tumor formation (Eischen et al.,
2001; Schmitt et al., 2002), observations used to argue that
the p19ARF/p53 pathway is principally involved in mediating an
apoptotic tumor suppressor program in response toMyc activa-
tion. There are several possible explanations for this apparent
inconsistency. First, the situation in lymphoid cells may not be
generally applicable to other cells types. Indeed, p53 activation
is known to trigger apoptosis efficiently in lymphoid cells but in
mesenchymal andmany epithelial lineages, as in b cells, replica-
tive arrest is a more common outcome, especially in vivo where
abundant survival factors often exist to suppress apoptotic re-
sponses. Second, our data indicate that p19ARF loss and p53
loss each exert a very different influence on Myc-induced apo-
ptosis in vivo: while p53 loss confers some measure of protec-
tion from apoptosis, p19ARF loss exacerbates it. Any functional
prosurvival complementation between Bcl-2 overexpression
and p53 loss is, therefore, unlikely to extend to loss of p19ARF.
More generally, loss of p19ARF and loss of p53 seem unlikely
to be equivalent since, even in the absence of p19ARF, p53
can still be activated by a wide variety of stress signals that
are likely to occur in developing tumors, including hypoxia and
DNA damage. Conversely, increasing evidence points to p53-
independent properties of p19ARF (Kelly-Spratt et al., 2004;
Kuo et al., 2003), in particular the induction of replicative arrest
through its actions on ribosome biogenesis (Ayrault et al.,
2004; Bertwistle et al., 2004; Sugimoto et al., 2003) and, asmen-
tioned, the possible inhibition of Myc itself (Datta et al., 2004;
Qi et al., 2004). Last, it is important to acknowledge that cancers
kill because tumor burden, for whatever reason, becomes lethal.
If either abrogation of apoptosis or loss of p53-induced growth
suppression is each, alone, sufficient to allow outgrowth of
a lethal Myc-induced tumor, then there would exist no signifi-
cant evolutionary pressure to select for additional mutations
in the other pathway before death of the organisms intervened.CANCER CELL AUGUST 2006
A R T I C L EThus, while our data clearly indicate that combining Bcl-xL over-
expression and p19ARF loss confers dramatic additional selec-
tive advantages on incipient tumor cells, it remains to be seen
how important their relative contributions are to naturally occur-
ring tumors that arise over the extended timescales that mark
human cancers.
Experimental procedures
Transgenic and knockout mice
Mice expressing MycERTAM under the control of the rat insulin promoter
(pIns-MycERTAM) (Pelengaris et al., 2002) were crossed with animals ex-
pressing Bcl-xL under the same promoter (RIP7-Bcl-xL mice [Zhou et al.,
2000]) or onto an ARF2/2 (Kamijo et al., 1997) or p532/2 (Donehower et al.,
1992) background. MycERTAM was activated in b cells in situ by daily i.p. in-
jection of Tamoxifen (1 mg/mouse/day) dissolved in peanut oil (Sigma). At
least five mice were used in each experimental cohort, and reproducibility
was extremely high, as described (Lawlor et al., 2006; Pelengaris et al.,
2002). To identify cells in S phase, mice were injected i.p. with 2 mmol
BrdU 3.5 hr prior to sacrifice. For histological analysis, pancreata were har-
vested, stored in Z-fix (Anatech Ltd, Battle Creek, MI) overnight, dehydrated,
and embedded in paraffin, and 5 mm sections were prepared. Alternatively,
pancreata were frozen in OCT compound (Sakura Finetek, Torrance, CA),
and 10 mm sections were prepared. All studies involving animal subjects
were performed in accordance with protocol number A10518-16702,
approved by the UCSF IACUC.
Histology and immunofluorescence
Tissue sections (5 mm) were rehydrated and boiled in 10 mM sodium citrate
(pH 6.0), for 5 min to recover antigens. Primary antibody (guinea pig anti-in-
sulin [Linco], rat monoclonal anti-CD31 [BD Pharmingen], rabbit monoclonal
anti-Ki67 [Neomarkers], rabbit polyclonals to p19ARF [Ab80; Abcam], p53
[CM5; Novocastra], ERa, and mouse monoclonal to p21cip1 [BD Pharmin-
gen]) was applied in blocking buffer (2.5% BSA, 5% goat serum, 0.3% Triton
X-100 in PBS) for 2–16 hr. Incorporated BrdU and apoptotic cells were de-
tected using a BrdU Detection kit II (Roche) and an Apoptag kit (Chemicon),
respectively, according to the manufacturers’ instructions. Secondary anti-
bodies (from Dako and Molecular Probes) were applied in blocking buffer
for 30 min. DAB development was accomplished using DAB reagents from
Vector laboratories. Fluorescent antibody-labeled slides were rinsed in
PBS and mounted in DAKO fluorescent mounting medium containing
1 mg/ml Hoechst. Fluorescence images were obtained in the Laboratory for
Cell Analysis (UCSF Comprehensive Cancer Center) using a LSM510 confo-
cal microscope (Zeiss) or an Axiovert 100 inverted microscope (Zeiss) equip-
ped with a Hamamatsu Orca digital camera. Apoptosis and BrdU incorpora-
tion were quantified in tissue sections by counting randomized fields of islet
cells and calculating the percentage of TUNEL- or BrdU-positive cells as
a percentage of insulin-positive cells.
Determination of blood glucose
Mice were fasted for 4 hr, and 50 ml samples of blood were collected from the
tail vein. Glucose levels were determined using Accu-Chek Active test strips
(Roche Diagnostics Corp., Indianapolis, IN).
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